
What is claimed is:

1. A compound of Formula III;



III

wherein each R^1 is independently H or C_{1-3}alkyl;

each R^2 is independently C_{1-3}alkyl;

on each carbon to which there are R^3 groups, either both R^3s are H or the R^3 groups together with the carbon to which they are bonded form a 4-, 5-, or 6-membered saturated spiro ring with the proviso that there is no more than 1 spiro ring on each saturated nitrogen-containing ring;

each saturated spiro formed from R^3 groups is independently cycloalkyl, or may contain 1 or 2 oxygen atoms, or 1 or 2 sulfur atoms, or 1 SO_2, or 1 NR^4;

each R^4 is independently H, $C(O)OC_{1-4}$alkyl, $C(O)C_{1-4}$alkyl, $C(O)NC_{1-4}$alkyl, SO_2C_{1-4}alkyl; and each spiro ring may optionally be substituted with deuterium, fluorine, or 1-2 methyl groups.


2. A compound according to Claim 1 wherein R^3 groups form a spiro ring on each of the two depicted saturated nitrogen-containing rings.

3. A compound according to Claim 2 wherein each of said spiro rings is bonded to the same relative carbon atom in each saturated nitrogen-containing ring.

4. A compound according to Claim 1 wherein R^3 groups form a spiro ring on only one of the two depicted saturated nitrogen-containing rings.

What is claimed is:

~~5~~1. A compound of Formula I;



I

wherein each R^1 is independently H or C_{1-3}alkyl;


each R^2 is independently C_{1-3}alkyl;

each X is independently CRR, O or S;

n is 2 or 3; and

each R is independently methyl, hydrogen, or deuterium.

~~6. A compound of Formula II;~~



~~II~~

~~wherein each R^1 is independently H or C_{1-3}alkyl;~~

~~each R^2 is independently C_{1-3}alkyl;~~

~~each X is independently CRR, O, or S;~~

~~each n is independently 2 or 3; and~~

~~each R is independently methyl, hydrogen, or deuterium.~~

~~7~~2. A compound according to Claim ~~5 or Claim 6~~1 wherein each X is identical.

~~8~~3. A compound according to ~~any of~~ Claims ~~5-7~~2 wherein X is S or O.


~~9~~4. A compound according to ~~any of~~ Claims ~~5-8~~3 wherein every CRR is CH_2.

~~10~~5. A compound according to ~~any of~~ Claim~~s~~ ~~5-8~~3 wherein no more than two Rs in each spiro are methyl.


~~11~~6. A compound according to ~~any preceding~~ claim 1 wherein each R^1 is isopropyl.

~~12~~7. A compound according to ~~any preceding~~ claim 1 wherein each R^2 is methyl.


~~13~~8. The compound



~~14~~9. The compound of Claim ~~13~~-8 wherein said compound is enantiomerically enriched with the following enantiomer



~~15~~10. A pharmaceutically acceptable salt of a compound ~~according to any preceding claim~~



~~16~~11. A salt according to Claim ~~15~~-10 wherein said salt is either a di-HCl salt or a sulfate salt.

~~17~~12. A salt according to Claim ~~16~~-11 wherein said salt is a sulfate salt.

~~18. A sulphate salt of the compound of Claim 13 or 14.~~

~~19~~13. A salt according to Claim ~~16, 17, or 18,~~12 wherein said salt is crystalline.

~~20~~14. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt ~~according to any preceding claim~~thereof.

~~21. A pharmaceutical composition comprising a compound according to Claim 13 or 14, or a salt according to claim 18.~~

~~22~~15. A pharmaceutical composition for use in the treatment of an HCV viral infection in a human, comprising a compound or salt as defined in any of Claims 1-~~19~~13.

~~23~~16. A compound or salt as defined in any of Claims 1 -~~19~~ 13 for use in the treatment of an HCV viral infection in a human.

~~24~~17. The use of a ~~compound or salt~~pharmaceutical composition according to claim 14 ~~as defined in any of Claims 1-19~~ in the manufacture of a medicament for ~~use in~~ the treatment of an HCV viral infection in a human.

~~25. The use of Claim 24 wherein said viral infection is an HCV infection.~~